417 related articles for article (PubMed ID: 24154874)
21. APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
Kosumi K; Baba Y; Ishimoto T; Harada K; Nakamura K; Ohuchi M; Kiyozumi Y; Izumi D; Tokunaga R; Taki K; Higashi T; Miyata T; Shigaki H; Kurashige J; Hiyoshi Y; Iwatsuki M; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Oki E; Watanabe M; Baba H
Med Oncol; 2016 Mar; 33(3):26. PubMed ID: 26880326
[TBL] [Abstract][Full Text] [Related]
22. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
23. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
24. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Nikkilä J; Kumar R; Campbell J; Brandsma I; Pemberton HN; Wallberg F; Nagy K; Scheer I; Vertessy BG; Serebrenik AA; Monni V; Harris RS; Pettitt SJ; Ashworth A; Lord CJ
Br J Cancer; 2017 Jun; 117(1):113-123. PubMed ID: 28535155
[TBL] [Abstract][Full Text] [Related]
25. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
Land AM; Wang J; Law EK; Aberle R; Kirmaier A; Krupp A; Johnson WE; Harris RS
Oncotarget; 2015 Nov; 6(37):39969-79. PubMed ID: 26544511
[TBL] [Abstract][Full Text] [Related]
26. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.
Salzman J; Marinelli RJ; Wang PL; Green AE; Nielsen JS; Nelson BH; Drescher CW; Brown PO
PLoS Biol; 2011 Sep; 9(9):e1001156. PubMed ID: 21949640
[TBL] [Abstract][Full Text] [Related]
27. Expression of hexokinase 2 in epithelial ovarian tumors and its clinical significance in serous ovarian cancer.
Jin Z; Gu J; Xin X; Li Y; Wang H
Eur J Gynaecol Oncol; 2014; 35(5):519-24. PubMed ID: 25423696
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
[TBL] [Abstract][Full Text] [Related]
29. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
[TBL] [Abstract][Full Text] [Related]
30. Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.
Ren C; Du J; Xi C; Yu Y; Hu A; Zhan J; Guo H; Fang W; Liu C; Zhang H
Biochem Biophys Res Commun; 2014 Mar; 446(1):187-94. PubMed ID: 24583125
[TBL] [Abstract][Full Text] [Related]
31. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
[TBL] [Abstract][Full Text] [Related]
32. Functional Upregulation of the DNA Cytosine Deaminase APOBEC3B by Polyomaviruses.
Verhalen B; Starrett GJ; Harris RS; Jiang M
J Virol; 2016 Jul; 90(14):6379-6386. PubMed ID: 27147740
[TBL] [Abstract][Full Text] [Related]
33. HPV-16/18 E6-induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of Cyclin D1.
Fan Q; Huang T; Sun X; Wang YW; Wang J; Liu Y; Ni T; Gu SL; Li YH; Wang YD
Mol Carcinog; 2021 May; 60(5):313-330. PubMed ID: 33631046
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
35. Whence High-Grade Serous Ovarian Cancer.
Kohn EC; Ivy SP
Am Soc Clin Oncol Educ Book; 2017; 37():443-448. PubMed ID: 28561656
[TBL] [Abstract][Full Text] [Related]
36. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
37. Evidence for APOBEC3B mRNA and protein expression in oral squamous cell carcinomas.
Fanourakis G; Tosios K; Papanikolaou N; Chatzistamou I; Xydous M; Tseleni-Balafouta S; Sklavounou A; Voutsinas GE; Vastardis H
Exp Mol Pathol; 2016 Dec; 101(3):314-319. PubMed ID: 27818121
[TBL] [Abstract][Full Text] [Related]
38. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
Kar SP; Adler E; Tyrer J; Hazelett D; Anton-Culver H; Bandera EV; Beckmann MW; Berchuck A; Bogdanova N; Brinton L; Butzow R; Campbell I; Carty K; Chang-Claude J; Cook LS; Cramer DW; Cunningham JM; Dansonka-Mieszkowska A; Doherty JA; Dörk T; Dürst M; Eccles D; Fasching PA; Flanagan J; Gentry-Maharaj A; Glasspool R; Goode EL; Goodman MT; Gronwald J; Heitz F; Hildebrandt MA; Høgdall E; Høgdall CK; Huntsman DG; Jensen A; Karlan BY; Kelemen LE; Kiemeney LA; Kjaer SK; Kupryjanczyk J; Lambrechts D; Levine DA; Li Q; Lissowska J; Lu KH; Lubiński J; Massuger LF; McGuire V; McNeish I; Menon U; Modugno F; Monteiro AN; Moysich KB; Ness RB; Nevanlinna H; Paul J; Pearce CL; Pejovic T; Permuth JB; Phelan C; Pike MC; Poole EM; Ramus SJ; Risch HA; Rossing MA; Salvesen HB; Schildkraut JM; Sellers TA; Sherman M; Siddiqui N; Sieh W; Song H; Southey M; Terry KL; Tworoger SS; Walsh C; Wentzensen N; Whittemore AS; Wu AH; Yang H; Zheng W; Ziogas A; Freedman ML; Gayther SA; Pharoah PD; Lawrenson K
Br J Cancer; 2017 Feb; 116(4):524-535. PubMed ID: 28103614
[TBL] [Abstract][Full Text] [Related]
39. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
[TBL] [Abstract][Full Text] [Related]
40. APOBEC3B: pathological consequences of an innate immune DNA mutator.
Burns MB; Leonard B; Harris RS
Biomed J; 2015; 38(2):102-10. PubMed ID: 25566802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
